PBD

Webcomics Global Market Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 18, 2024
Online, Mobile Entertainment, Books, Other Entertainment, Entertainment, Romantic, BookScan, Empowerment, Lore Olympus, Webtoon (platform), Social media, Traction, City, HYBE, Growth, Pew Research Center, Computer, BTS, Pew, PBD, Prevalence, NYT

The "Webcomics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Webcomics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
  • The webcomics market size is expected to see strong growth in the next few years.
  • The anticipated rise in the usage of smart devices is set to drive the growth of the webcomics market in the projected period.
  • The countries covered in the webcomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Relyance AI Named a 2023 Gartner® Cool Vendor™ in Privacy

Retrieved on: 
Monday, August 21, 2023
Online Privacy, Data Management, Security, Technology, Software, Artificial Intelligence, Heart, Natural language processing, Metadata, Gartner, Classification, Risk management, Research, NLP, Assistant, Organization, Publication, Entrepreneurship, AI, API, PBD, Cool, Natural language, Medical device, Online shopping, Privacy, New Relic

Relyance AI , an AI-powered data protection and governance platform focused on building trust, has been recognized as a Cool Vendor™ in Privacy by leading analyst firm Gartner®.

Key Points: 
  • Relyance AI , an AI-powered data protection and governance platform focused on building trust, has been recognized as a Cool Vendor™ in Privacy by leading analyst firm Gartner®.
  • Every year, Gartner identifies and recognizes organizations in its series of Cool Vendor reports that highlight interesting, new and innovative vendors, products and services.
  • In the 2023 Cool Vendors in Privacy report, Gartner spotlights Relyance AI as one of five privacy vendors with solutions that support maturing privacy programs in detail, covering privacy as code and protection of data-in-use.
  • The AI-powered platform automatically inventories data assets and maps data flows, which is critical for an organization to achieve privacy compliance.

Relyance AI Named to CB Insights’ 2023 AI 100 Global List of Most Promising Artificial Intelligence Companies

Retrieved on: 
Tuesday, June 27, 2023
Security, Data Management, Technology, Artificial Intelligence, Software, Heart, Natural language processing, Metadata, Classification, CB, Privacy, CB Insights, Public Facilities Privacy & Security Act, NLP, Entrepreneurship, R, AI, PBD, Natural language, Medical device, New Relic

CB Insights, a leading global market research firm, has recognized Relyance AI, an AI-powered data protection and governance platform focused on building trust, on its 2023 “AI 100” list of the world’s 100 most promising private AI companies.

Key Points: 
  • CB Insights, a leading global market research firm, has recognized Relyance AI, an AI-powered data protection and governance platform focused on building trust, on its 2023 “AI 100” list of the world’s 100 most promising private AI companies.
  • Relyance AI was selected as one of the top in the Privacy & Security category for its innovative code scanning and machine learning technology.
  • This is the first time that Relyance AI has been recognized by CB Insights.
  • The companies named to this year’s list were selected by the CB Insights research team from a pool of more than 7,000 private companies worldwide.

Latest eufy Security and Anker PowerHouse Products Showcased at SecurEX South Africa

Retrieved on: 
Tuesday, June 6, 2023
Lithium, Anker Innovations, Anker, Emergency, Powerhouse, TB, Lithium iron phosphate, Privacy, PBD, Security, Pet, AI, Video game, African

PRETORIA, South Africa, June 6, 2023 /PRNewswire/ -- Premium Brand Distributors (PBD), a leading South African technology distributor, recently debuted at SecurEX South Africa, showcasing the latest from eufy Security and Anker PowerHouse.

Key Points: 
  • PRETORIA, South Africa, June 6, 2023 /PRNewswire/ -- Premium Brand Distributors (PBD), a leading South African technology distributor, recently debuted at SecurEX South Africa, showcasing the latest from eufy Security and Anker PowerHouse.
  • Grant Norton, CEO of Premium Brand Distributors, expressed excitement about bringing Anker Innovations' eufy Security and Anker PowerHouse products to the vibrant South African market.
  • Faraz Mehdi, General Manager of Anker Innovations, Middle East, Africa, and South Asia, recognized the value of the South African market and expressed the privilege of offering their state-of-the-art eufy Security and Anker PowerHouse solutions through PBD.
  • By partnering with eufy Security and Anker PowerHouse, PBD sought to revolutionize how consumers approached security and portable power.

Latest eufy Security and Anker PowerHouse Products Showcased at SecurEX South Africa

Retrieved on: 
Tuesday, June 6, 2023
Lithium, Anker Innovations, Anker, Emergency, Powerhouse, TB, Lithium iron phosphate, Multimedia, Privacy, PBD, Security, Pet, AI, Video game, Online shopping, African

PRETORIA, South Africa, June 6, 2023 /PRNewswire/ -- Premium Brand Distributors (PBD), a leading South African technology distributor, recently debuted at SecurEX South Africa, showcasing the latest from eufy Security and Anker PowerHouse.

Key Points: 
  • PRETORIA, South Africa, June 6, 2023 /PRNewswire/ -- Premium Brand Distributors (PBD), a leading South African technology distributor, recently debuted at SecurEX South Africa, showcasing the latest from eufy Security and Anker PowerHouse.
  • Grant Norton, CEO of Premium Brand Distributors, expressed excitement about bringing Anker Innovations' eufy Security and Anker PowerHouse products to the vibrant South African market.
  • Faraz Mehdi, General Manager of Anker Innovations, Middle East, Africa, and South Asia, recognized the value of the South African market and expressed the privilege of offering their state-of-the-art eufy Security and Anker PowerHouse solutions through PBD.
  • By partnering with eufy Security and Anker PowerHouse, PBD sought to revolutionize how consumers approached security and portable power.

Relyance AI Selected as Top 10 Cybersecurity Finalist to Compete in RSA’s 2023 Innovation Sandbox Contest

Retrieved on: 
Tuesday, March 28, 2023
Data Management, Online Privacy, Security, Technology, Software, Artificial Intelligence, Internet, Linda, SDLC, Heart, Natural language processing, Metadata, Senior, Cato Networks, Face, Classification, General partnership, RSA Conference, Microsoft, Privacy, Independent Research Fund Denmark, NLP, RSA, Motion, Moscone Center, Investment, Risk, CO, PBD, Conference, Natural language, Medical device, Cryptocurrency

Relyance AI, a data protection and governance platform focused on building trust, has been named one of 10 finalists for the RSA Conference™ 2023 Innovation Sandbox contest for its innovative, code scanning and machine learning technology.

Key Points: 
  • Relyance AI, a data protection and governance platform focused on building trust, has been named one of 10 finalists for the RSA Conference™ 2023 Innovation Sandbox contest for its innovative, code scanning and machine learning technology.
  • Relyance will present its paradigm shifting platform to a panel of renowned industry judges and a live in-person audience on Monday, April 24, at the RSA Conference 2023 in San Francisco.
  • Hugh Thompson, Program Committee Chair of RSA Conference, will return to host the contest.
  • For more information regarding RSA Conference 2023, taking place at the Moscone Center in San Francisco from April 24-27, please visit https://www.rsaconference.com/usa .

Sensitive Data Protection Still Major Challenge for Enterprises

Retrieved on: 
Thursday, February 23, 2023
Research report, Privacy, Information, Organization, Risk, Perception, TEL, PBD, Social Security, Intellectual property, Identity theft, PII, Risk management, Online shopping, Design

It is likely that this lack of emphasis has contributed to the growing number of sensitive data breaches.

Key Points: 
  • It is likely that this lack of emphasis has contributed to the growing number of sensitive data breaches.
  • Piiano’s research reveals that while at least 76% of participating companies protect PII differently from non-PII data, 54% do not treat PII protection as a high priority.
  • This approach also helps enterprises allocate resources more effectively and ensure that their privacy protection efforts have the greatest impact.
  • Moreover, sensitive data leaks can tarnish an organization's reputation, damage customer trust and create losses of revenue.

ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer

Retrieved on: 
Monday, December 19, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Rubius, CFO, PBD, El Rubius, Stock dilution, Patient, NYSE, B-cell lymphoma, Control, Lymphatic system, Novartis, Partnership, Growth, ADC, FDA, Multimedia, Information technology, Therapy, Diffuse large B-cell lymphoma, Hotspot, Cancer, Management, Fine chemical, San Francisco Bay Area

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.
  • As we enter the next phase of growth, I am confident that his extensive financial background, deep capital markets experience and proven leadership in the pharmaceutical industry will help drive our corporate objectives and deliver long-term value for shareholders,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
  • He most recently served as CFO of Rubius Therapeutics where he was responsible for all financial functions as well as business development, investor relations, information technology and procurement.
  • “I am thrilled to join ADC Therapeutics, especially at this exciting point in the Company’s evolution,” said Mr. Carmona.

Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Retrieved on: 
Wednesday, December 21, 2022
NYSE, Food, Malignancy, Disease, PMC, Safety, EMA, PBD, US Foods, Patient, Research and development, Nasdaq Stockholm, B-cell lymphoma, Lymphoma, Marketing, Lymphoid leukemia, FDA, Diffuse large B-cell lymphoma, Development, EC, SEK, Genetics, Committee, Control, Lymphatic system, Cancer research, ADC, Enzyme, DNA, Therapy, Degenerative disease, Incidence, Distortion, Cancer, Cancer Research UK, European Commission, Induced cell cycle arrest, USD, European Commission–AstraZeneca COVID-19 vaccine dispute, DNA repair, Medical Affairs Bureau, Pharmaceutical industry, Fine chemical, San Francisco Bay Area, DLBCL, Swedish Orphan Biovitrum, EU, Loncastuximab tesirine

"We are thrilled that Zynlonta will be available to help fill a critical unmet need for patients with DLBCL across Europe."

Key Points: 
  • "We are thrilled that Zynlonta will be available to help fill a critical unmet need for patients with DLBCL across Europe."
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive and malignant disease in haematology with an incidence in Europe of approximately 8.8 cases per 100,000 adults per year1.
  • ADC Therapeutics' CD19-directed ADC Zynlonta (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy.
  • Postal address SE-112 76 Stockholm, Sweden
    For details on how to contact the Sobi Investor Relations Team, please click here .

FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS

Retrieved on: 
Monday, December 12, 2022
Heme, Therapy, DLBCL, Lymphatic system, Immune system, PBD, Society, Biomarker, Patient, Cancer, ADC, Research, Biology, NYSE, Diffuse large B-cell lymphoma, FDA, Molecular biology, Nucleic acid thermodynamics, Multimedia, Loncastuximab tesirine, Control, SAN, Blood, Machine learning, ASH, Hodgkin lymphoma, Medical imaging, Fine chemical, Pharmaceutical industry, San Francisco Bay Area, Catriona lonca, Camisole

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 /PRNewswire/ -- Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans.

Key Points: 
  • The findings presented at ASH show promise in identifying biomarkers associated with response to lonca and also suggested mechanisms of resistance seen in non-responders, which may inform future drug combination research.
  • "We look forward to further exploration of these findings to determine their significance for healthcare providers trying to identify the most appropriate treatments for patients with DLBCL."
  • "ADC Therapeutics is a leader in the field of antibody-drug conjugates," said Mike Nolan , chief executive officer, Freenome.
  • The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.